TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02410954

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NeuroConn Direct Current stimulator Multiple Channel -4
Description: (tDCS) will be administered with a multichannel tDCS device that can be programmed so that the operator doesn't know the combination of electrodes being used for stimulation, and, thereby allow double-blinding. The active tDCS electrode configuration to be used will be determined with the 3 round iterative procedure described above; based on electric field modeling and personalized electrical dose titration to find the lowest dose that is well-tolerated and engages the target in terms of inhibiting the AOT pupillary response.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroConn Direct Current stimulator Multiple Channel -4
Description: (tDCS) will be administered with a multichannel tDCS device that can be programmed so that the operator doesn't know the combination of electrodes being used for stimulation, and, thereby allow double-blinding. The active tDCS electrode configuration to be used will be determined with the 3 round iterative procedure described above; based on electric field modeling and personalized electrical dose titration to find the lowest dose that is well-tolerated and engages the target in terms of inhibiting the AOT pupillary response.
Study: NCT02845778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Each sachet contains 0.5 g

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Each sachet contains 0.5 g
Study: NCT01887119

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eplerenone-matched placebo
Study: NCT03400657

Intervention type: PROCEDURE
Intervention: Multi-disciplinary Treatment
Description: due to suggestion of Multi-disciplinary Treatment ,the patients would be suggested to chemotherapy or surgery.

Intervention type: PROCEDURE
Intervention: Multi-disciplinary Treatment
Description: due to suggestion of Multi-disciplinary Treatment ,the patients would be suggested to chemotherapy or surgery.

Intervention type: PROCEDURE
Intervention: Multi-disciplinary Treatment
Description: due to suggestion of Multi-disciplinary Treatment ,the patients would be suggested to chemotherapy or surgery.
Study: NCT03778320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-692
Description: Single oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-Serine
Description: Single oral dose
Study: NCT03781219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL-085
Description: HL-085 ( Capsule) is one MEK inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib ( Tablet) is BRAF inhibitor,
Study: NCT00600691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: one tablet (5mg) of finasteride
Study: NCT04798534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Service decentralization facilitation intervention
Description: The intervention CHW will participate in three 60-minute intervention weekly sessions. During the intervention, CHW will be provided with the knowledge and skills to serve their MMT patients. The intervention sessions will also focus on enhancing the current service decentralization workflow so that the CHW can work with both their peer providers and their patients more efficiently. Two-times booster sessions will be offered before the 3- and 6-month survey for continued skill building for problem-solving. In addition to the group sessions, the intervention arm CHW will be encouraged to use a specially designed online platform to review the current policy and scientific findings, review their patients' treatment status, communicate with other providers, and provide instant consulting to their MMT patients. The MMT patients in the intervention condition can use the online platform to communicate with their CHW and view education materials disseminated by their MMT providers or CHW.
Study: NCT00042926

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymphangiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radionuclide imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sentinel lymph node biopsy
Study: NCT02350387

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Intensity Short Duration Exercise
Description: Participants randomized to this group will perform 4 sets of 8-15 repetitions of eccentric exercise using the Eccentron set at 50-80% of the participant's one repetition maximum.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low intensity Long Duration Exercise
Description: Participants randomized to this group will perform 5-20 minutes of continuous eccentric exercise using the Eccentron set at 50% of the participant's one repetition maximum.
Study: NCT02061046

Intervention type: DEVICE
Intervention: CPAP therapy
Description: 8 weeks of CPAP therapy
Study: NCT03728491

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simulator
Description: US Mentor simulator, lung module, provided by 3D Healthcare Systems

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Healthy figurants
Description: Medical students or volunteers without any pathology in thorax
Study: NCT01976897

Intervention type: OTHER
Intervention: Knee flexion measurement 1
Description: The angle of knee flexion during resting, supine position is measured by a first person.

Intervention type: OTHER
Intervention: Knee flexion measurement 2
Description: The angle of knee flexion during resting, supine position is measured by a second person.

Intervention type: OTHER
Intervention: Heel - interface pressure measurements
Description: The pressure analysis system used is the X Sensor X3 model (Xsensor Technology Corporation, Calgary, Canada). The sensor mat is made up of transducer cells, each measuring 1.6 cm\^2. The digital signal is transmitted to a PC via a USB port at a sampling frequency of 10Hz. Before each measurement, the sensor mat is calibrated from 10 to 220 mm Hg, according to the manufacturer's recommendations.~The sheet of pressure sensors is disposed on the dedicated bed. The patient is then asked to take his/her usual position in the supine position and a latency of 5 minutes is observed. The recording time pressure is then performed for 90 seconds in the optical observing time to adapt to changes in media.
Study: NCT04451824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CL-100
Description: Red Light LED device for circumferential reduction
Study: NCT02607540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 cycles cisplatin-5-fluorouracil
Description: 2 cycles cisplatin-5-fluorouracil(PF 2 cycles): cisplatin: 75mg/m2 d1，29; 5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 4 cycles cisplatin-5-fluorouracil
Description: 4 cycles cisplatin-5-fluoroura(PF 4 cycles): cilcisplatin: 75mg/m2 d1，29, 57, 85; 5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32, d57-60, d85-88.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
Study: NCT00042926

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: technetium Tc 99m sulfur colloid
Study: NCT04642924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGM-101
Description: Fluorescence-guided surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGM-101
Description: Fluorescence-guided surgery
Study: NCT02761577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: 3 mL/kg/hour of Sodium bicarbonate, an hour prior to angiography and 1 mL/kg/hour, within six hours after angiography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: 3 mL/kg/hour of Sodium bicarbonate, an hour prior to angiography and 1 mL/kg/hour, within six hours after angiography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine (1200 mg twice a day, IV (in vein) ) one day before angiography, on the day of the angiography, and one day after the diagnostic procedure
Study: NCT02452398

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment group
Description: The intense pulsed light (IPL) applicator with a wavelength of 690 nm and spot size (treatment area) of 30 mm by 10 mm will be used to deliver the energy to the treatment area.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: Subject will act as their own control where the baseline hair count will be used as a comparator to the hair count after treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: Subject will act as their own control where the baseline hair count will be used as a comparator to the hair count after treatment.
Study: NCT01705158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin and liposomal doxorubicin
Description: Carboplatin AUC5 and liposomal doxorubicin 40 or 50 mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops.
Study: NCT04484623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Immunomodulatory drug (IMiD) will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Immunomodulatory drug (IMiD) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Synthetic glucocorticoid with anti-tumor activity will be administered.
Study: NCT03481634

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Intravitreal injection
Study: NCT04484623

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Synthetic glucocorticoid with anti-tumor activity will be administered.
Study: NCT00627003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline
Description: Cabergoline oral tablets administered once daily in the evening: 0.5 mg daily on Days 1 to 3, 1.0 mg daily on Days 4 to 7, 1.5 mg daily on Days 8 to 10, and 2.0 mg daily on Days 11 to 14, followed by a stable dose for an additional 3 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral tablets administered daily for 5 weeks
Study: NCT04216017

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: kenalog
Description: Cortisone injection into shoulder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine injection into shoulder
Study: NCT04484623

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Proteasome Inhibitor will be administered.
Study: NCT00510133

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRNVAC1
Description: Autologous dendritic cell vaccine
Study: NCT01119131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 at 10,000 IU a day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: calcium
Description: 1000mg calcium daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: calcium
Description: 1000mg calcium daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo pill with similar appearance to the vitamin D3 will be given to those in the placebo arm
Study: NCT04170257

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endoscopic examination using white light, NBI and iodine staining
Description: Participants' esophagus will be examined by three commonly used diagnostic techniques in the order of : 1. White light endoscopy (WLE); 2. Narrow Band Imaging (NBI) and 3. Iodine Staining Endoscopy (ISE) with 1.2% Lugol's iodine solution. The required observation time is no less than 1 minute for WLE and 2 minutes for NBI and ISE. Endoscopic images of each participant are routinely captured at every 5 centimeters in the esophagus, and information is recorded in detail for each focal lesion. Biopsies are taken from all visually abnormal areas found by any one of the three techniques, histopathologic diagnoses are rendered by two pathologists according to standard criteria and discrepancies are adjudicated by consultation. The recorded endoscopic images for each biopsied lesion are read by two trained researchers and the visualized feature of lesions are decomposed into several indicators (e.g. size, shape, color, and border of lesions) .
Study: NCT01529840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit
Study: NCT05283057

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 25 MG
Description: single dose of the SGLT inhibitor Empagliflozin was given

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single dose of placebo that is similar to Empagliflozin in physical appearance
Study: NCT03533179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Glucagon 1 mg/ml solution is dissolved in 50 ml isotonic fluid and injected as bolus corresponding to 50 micrograms/kg over 1-3 minutes from time=0 on day C+E. on day D (glucagon 2), 50 micrograms/kg of glucagon is infused over 30 minutes from time=0 to time =30.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Glucagon 1 mg/ml solution is dissolved in 50 ml isotonic fluid and injected as bolus corresponding to 50 micrograms/kg over 1-3 minutes from time=0 on day C+E. on day D (glucagon 2), 50 micrograms/kg of glucagon is infused over 30 minutes from time=0 to time =30.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Glucagon 1 mg/ml solution is dissolved in 50 ml isotonic fluid and injected as bolus corresponding to 50 micrograms/kg over 1-3 minutes from time=0 on day C+E. on day D (glucagon 2), 50 micrograms/kg of glucagon is infused over 30 minutes from time=0 to time =30.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: Esmolol hydrochloride 10 mg/ml is infused from time -15 min to time + 30 minutes as an initial bolus followed by an infusion. infusion rate is tapered if heart rate declines below 30 beats per minute (bpm) or \>25 % from baseline, systolic blood pressure decreases below 80 mmHg or the participant experiences side effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: Esmolol hydrochloride 10 mg/ml is infused from time -15 min to time + 30 minutes as an initial bolus followed by an infusion. infusion rate is tapered if heart rate declines below 30 beats per minute (bpm) or \>25 % from baseline, systolic blood pressure decreases below 80 mmHg or the participant experiences side effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physiologic saline - glucagon dummy
Description: Isotonic 0.9 % sodium chloride solution is administered as matching placebo to glucagon, and injected in identical rates on corresponding days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physiologic saline - glucagon dummy
Description: Isotonic 0.9 % sodium chloride solution is administered as matching placebo to glucagon, and injected in identical rates on corresponding days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physiologic saline - esmolol dummy
Description: Isotonic 0.9 % sodium chloride solution is administered as matching placebo to esmolol, and injected in identical rates on corresponding days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physiologic saline - esmolol dummy
Description: Isotonic 0.9 % sodium chloride solution is administered as matching placebo to esmolol, and injected in identical rates on corresponding days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Physiologic saline - esmolol dummy
Description: Isotonic 0.9 % sodium chloride solution is administered as matching placebo to esmolol, and injected in identical rates on corresponding days.
Study: NCT02414334

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy (SABR)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Ablative Radiotherapy (SABR)
Study: NCT04264598

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV
Description: The Medium dosage sIPV was developed by Minhai Biotech Co., LTD. The antigen contents of type I, type II and type III polioviruses in the medium dosage sIPV were 15 DU, 45 DU and 45 DU. The vaccine was in liquid form, 0.5 ml per dose.
Study: NCT03875807

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACLR done at 0 degrees KFA
Description: Patients randomized to this arm will undergo the following intervention: Anterior Cruciate Ligament Reconstruction (ACLR) done at 0 degrees knee angle flexion (KFA)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACLR done at 30 degrees KFA
Description: Patients randomized to this arm will undergo the following intervention: Anterior Cruciate Ligament Reconstruction (ACLR) done at 30 degrees knee angle flexion (KFA)
Study: NCT04264598

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV
Description: The Medium dosage sIPV was developed by Minhai Biotech Co., LTD. The antigen contents of type I, type II and type III polioviruses in the medium dosage sIPV were 15 DU, 45 DU and 45 DU. The vaccine was in liquid form, 0.5 ml per dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV
Description: The Medium dosage sIPV was developed by Minhai Biotech Co., LTD. The antigen contents of type I, type II and type III polioviruses in the medium dosage sIPV were 15 DU, 45 DU and 45 DU. The vaccine was in liquid form, 0.5 ml per dose.
Study: NCT03342352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab administered intravenously at the protocol-defined dose every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab administered intravenously at the protocol-defined dose every 3 weeks.
Study: NCT05266300

Intervention type: GENETIC
Intervention: DPYD genotype
Description: The SNPs included in this study are the following (dbSNP Reference SNP)~rs3918290(c.1905+1G\>A) rs67376798(c.2846A\>T) rs55886062(c.1679T\>G) rs56038477(75017182)/(c.1236G\>A)
Study: NCT02502019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEMOBLAST Bellows
Description: HEMOBLAST™ Bellows is intended for use in surgical procedures as an adjunct to hemostasis when control of bleeding by conventional procedures is ineffective or impractical.
Study: NCT03413826

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The intervention groups will perform aerobic exercise for 12 weeks, expending 3,000 kcal of energy per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The intervention groups will perform aerobic exercise for 12 weeks, expending 3,000 kcal of energy per week.
Study: NCT01472406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sansum Closed-Loop Artificial Pancreas
Description: The Sansum Closed-loop Artificial Pancreas Device is the infrastructure that allows communication between the insulin pump, the CGM, the zone-MPC, and the HMS.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin infusion pump
Description: The insulin pump, which has received 510k clearance (K080639), delivers insulin subcutaneously through an infusion set.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor
Description: The CGM, which is an approved device (P050012), measures interstitial glucose.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: zone-Model Predictive Control algorithm
Description: The zone-MPC predicts future glucose values, based on CGM data, to regulate blood glucose level by increasing, decreasing, or stopping insulin infusion via an insulin infusion pump.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Safety Health Monitoring System
Description: The HMS predicts future glucose values, based on CGM data, to warn the Sansum Closed-loop Artificial Pancreas Device of values below 70 mg/dL.
Study: NCT02759575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg every 3 weeks starting 3 weeks prior to chemoradiotherapy. Maximum of 4 doses

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 70 Gy in 35 fractions over 7 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 100 mg/m2 every 3 weeks starting on day 1 of chemoradiotherapy. Maximum of 3 doses.
Study: NCT02055976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bococizumab (PF-04950615;RN316)
Description: Atorvastatin plus PF-04950615 50 mg subcutaneous administration at every two weeks (Q14D SC) for 16 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bococizumab (PF-04950615;RN316)
Description: Atorvastatin plus PF-04950615 100 mg Q14D SC for 16 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bococizumab (PF-04950615;RN316)
Description: Atorvastatin plus PF-04950615 150 mg Q14D SC for 16 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Atorvastatin plus PF-04950615 Placebo Q14D SC for 16 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Atorvastatin plus Ezetimibe 10 mg oral administration once daily for 16 week (open)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bococizumab (PF-04950615;RN316)
Description: 50 mg Q14D SC for 16 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bococizumab (PF-04950615;RN316)
Description: 100 mg Q14D SC for 16 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bococizumab (PF-04950615;RN316)
Description: 150 mg Q14D SC for 16 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Q14D SC for 16 week